The Semler Vision: Monetary and Medical Freedom Bitcoin Backed by Early Detection of Chronic Diseases August 4, 2025 Forward-Looking Statements . This presentation includes strbements that are, or may be deemed, "forward-looking statements." In some cases, hese forward-looling statements can be identified by the us looking terminabogy, including the terms "believe," "estimate," "anticipate," "expect," "plan," "intend," "may," "could," "might" "will," "should," or, in ecch case, their variations thereon or c ...

Core Insights - Semler Scientific, Inc. has reported significant progress in its Bitcoin treasury strategy, purchasing approximately $195.4 million of Bitcoin, bringing total holdings to nearly $586.2 million as of July 31, 2025, with unrealized gains exceeding $110.4 million and a BTC yield of 31.3% year-to-date [2][9][10] - The company launched CardioVanta™, a subsidiary focused on healthcare initiatives for early detection of heart failure and cardiac arrhythmia, positioning itself as a dual-engine platform for growth [2][26] - Financial results for Q2 2025 show revenues of $8.2 million, a 43% decrease year-over-year, and a net income of $66.9 million, significantly up from $11 thousand in Q2 2024 [10][11] Bitcoin Treasury Highlights - As of June 30, 2025, Semler Scientific held 4,636 Bitcoins valued at $496.9 million, reflecting a cumulative increase in fair value of $66.9 million [9][10] - The company purchased 1,444 Bitcoins for $149.6 million during Q2 2025 and an additional 385 Bitcoins for $45.8 million through July 31, 2025 [9][10] - Total Bitcoin holdings as of July 31, 2025, reached 5,021 Bitcoins with a fair value of $586.2 million [9][10] Financial Performance - Total operating expenses for Q2 2025 were $10.3 million, compared to $9.1 million in Q2 2024, with a loss from operations of $2.1 million [10][11] - Pre-tax income for Q2 2025 was $80.6 million, influenced by an unrealized gain of $83.8 million from Bitcoin holdings [10][11] - The effective tax rate for Q2 2025 was 17%, compared to 99% in Q2 2024 [10][11] Customer Concentration - The two largest customers accounted for 45% and 31% of Q2 2025 revenues, while the three largest customers in Q2 2024 accounted for 44%, 27%, and 11% of revenues [5][10] Cash Flow and Financing Activities - The company reported a net cash increase of $4.7 million for the period, with significant cash flows from financing activities, including $156.9 million from the issuance of common stock [13][10] - Semler Scientific has entered into a new Controlled Equity OfferingSM Sales Agreement allowing it to issue up to $500 million in common stock [9][10]